PharmAla Biotech

Toronto, Canada Founded: 2021 • Age: 5 yrs
Biomanufacturing, regulatory, and financial services are provided by PharmAla Biotech.
Annual revenue $440,329 Latest available
Total funding - 3 rounds
Employees - Tracked headcount
Investors - Known backers
Products 2 Services tracked
Competitors 8 Brand Intelligence

About PharmAla Biotech

PharmAla Biotech is a company based in Toronto (Canada) founded in 2021. PharmAla Biotech offers products and services including LaNeo™ MDMA and Novel MDXX Compounds. PharmAla Biotech operates in a competitive market with competitors including MCRA, Blue Matter Consulting, CHDR, S-Cubed and CATALIS, among others.

  • Headquarter Toronto, Canada
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Pharmala Biotech Holdings, Inc.
Operational Areas
Healthcare → Healthcare Services & Infrastructure Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $440.33 K (USD)
    -41.51
    as on Aug 31, 2025
  • Net Profit
    -$1.59 M (USD)
    -164.12
    as on Aug 31, 2025
  • EBITDA
    -$1.48 M (USD)
    -241.66
    as on Aug 31, 2025
  • Latest Funding Round
    $1.09 M (USD), Post-IPO

    Dec 20, 2024

  • Investors
    Not available
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of PharmAla Biotech

PharmAla Biotech is a publicly listed company on the CSE with ticker symbol MDMA in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: CSE · Ticker: MDMA · Sector: Health technology · Canada

Products & Services of PharmAla Biotech

PharmAla Biotech offers a comprehensive portfolio of products and services, including LaNeo™ MDMA and Novel MDXX Compounds.

Product name locked
Category locked
Primary

Clinical-grade MDMA for research and therapeutic applications.

Product name locked
Category locked
Locked

Improved MDMA analogs to enhance safety for various disorders.

Funding Insights of PharmAla Biotech

Investments & Acquisitions by PharmAla Biotech

Investments
Premium access

Investment portfolio details for PharmAla Biotech

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - PharmAla Biotech

Premium access

Detailed financials for PharmAla Biotech

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Pharmala Biotech Comparisons

PharmAla Biotech Primary company
Description
Biomanufacturing, regulatory, and financial services are pro...
Location
Toronto, Canada
Founded Year
2021
Annual Revenue
$440.33 K (USD)
Net Profit
-$1.59 M (USD)
EBITDA
-$1.48 M (USD)
Employees
Not available
Premium access

Peer comparison for PharmAla Biotech

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of PharmAla Biotech

PharmAla Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MCRA, Blue Matter Consulting, CHDR, S-Cubed and CATALIS, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Provider of regulatory, quality assurance and market access services to biopharma sector
Locked Locked Locked
Provider of consulting services focused for clinical drug development
Locked Locked Locked
Early-stage clinical drug research consulting services are provided.
Locked Locked Locked
Specialized consulting in clinical biometrics and regulatory affairs is provided.
Locked Locked Locked
Consulting services for clinical drug development and trials are provided.
Premium access

Detailed competitors of PharmAla Biotech

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Pharmala Biotech

Premium access

Complete news archive for PharmAla Biotech

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about PharmAla Biotech

PharmAla Biotech was founded in 2021 and raised its 1st funding round 2 years after it was founded.

PharmAla Biotech is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.

Annual revenue of PharmAla Biotech is $440.33K as on Aug 31, 2025.

PharmAla Biotech was founded in 2021 and is based in Toronto, Canada. Operations focus on the biotechnology sector, where biomanufacturing processes are supported alongside regulatory compliance and financial advisory services. These offerings assist clients in navigating production, approval, and funding challenges within the industry. The companys domain, pharmala.ca, serves as the primary online presence for these activities.

PharmAla Biotech's top competitors include S-Cubed, Vasta Global and Blue Matter Consulting.

PharmAla Biotech offers LaNeo™ MDMA and Novel MDXX Compounds.

Yes, PharmAla Biotech is publicly traded on CSE under the ticker symbol MDMA.

The ticker symbol of PharmAla Biotech is MDMA on CSE.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available